Elevated BDNF protein level in cortex but not in hippocampus of MDMA-treated Dark Agouti rats: A potential link to the long-term recovery of serotonergic axons

C. Ádori, Rómeó D. Andó, Linda Ferrington, Mária Szekeres, Szilvia Vas, Paul A T Kelly, L. Hunyady, G. Bagdy

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

3,4-Methylenedioxymethamphetamine (MDMA, " ecstasy" ) is a widely used recreational drug known to cause selective long-term serotonergic damage. In this study, we examined the pattern of BDNF protein expression 1 day, 3, 8, 12 and 24 weeks after a single 15mg/kg i.p. dose of MDMA to adolescent Dark Agouti rats. In parallel, we measured either tryptophan-hydroxylase immunoreactive (TpH IR) axon density, or [3H]-paroxetine-binding in parietal cortex and hippocampus, two brain areas known to have different recovery capacity after MDMA, to test whether BDNF-levels were associated with the long-term recovery of serotonergic fibers after a neurotoxic dose of MDMA. Both TpH IR axon density and [3H]-paroxetine-binding were significantly decreased 3 weeks after the treatment in both brain areas but while normalization in both parameters was found in parietal cortex 24 weeks after treatment, significant decreases remained evident in the hippocampus. In the parietal cortex, a significant reduction in BDNF protein levels was found in the acute phase after treatment (1 day), which was followed by a robust increase 8 weeks later and a return to control levels by 12 weeks. In contrast, no significant alteration of BDNF protein level was found in the hippocampus at any time points. This absence of any significant increase in BDNF protein levels in the hippocampus, and the persistence in this region of decreases in TpH IR axon density and [3H]-paroxetine-binding, raises the possibility that BDNF has an important role in the long-term recovery of serotonergic axons after MDMA treatment.

Original languageEnglish
Pages (from-to)56-60
Number of pages5
JournalNeuroscience Letters
Volume478
Issue number2
DOIs
Publication statusPublished - Jul 2010

Fingerprint

N-Methyl-3,4-methylenedioxyamphetamine
Brain-Derived Neurotrophic Factor
Axons
Hippocampus
Tryptophan Hydroxylase
Paroxetine
Parietal Lobe
Proteins
Brain
Street Drugs
Dasyproctidae

Keywords

  • 3,4-Methylenedioxymethamphetamine (ecstasy)
  • Brain derived neurotrophic factor (BDNF)
  • ELISA
  • Paroxetine-binding
  • Serotonin
  • Tryptophan-hydroxylase (TpH)

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Elevated BDNF protein level in cortex but not in hippocampus of MDMA-treated Dark Agouti rats : A potential link to the long-term recovery of serotonergic axons. / Ádori, C.; Andó, Rómeó D.; Ferrington, Linda; Szekeres, Mária; Vas, Szilvia; Kelly, Paul A T; Hunyady, L.; Bagdy, G.

In: Neuroscience Letters, Vol. 478, No. 2, 07.2010, p. 56-60.

Research output: Contribution to journalArticle

@article{1221094c24274548a80fa5fc2812baa8,
title = "Elevated BDNF protein level in cortex but not in hippocampus of MDMA-treated Dark Agouti rats: A potential link to the long-term recovery of serotonergic axons",
abstract = "3,4-Methylenedioxymethamphetamine (MDMA, {"} ecstasy{"} ) is a widely used recreational drug known to cause selective long-term serotonergic damage. In this study, we examined the pattern of BDNF protein expression 1 day, 3, 8, 12 and 24 weeks after a single 15mg/kg i.p. dose of MDMA to adolescent Dark Agouti rats. In parallel, we measured either tryptophan-hydroxylase immunoreactive (TpH IR) axon density, or [3H]-paroxetine-binding in parietal cortex and hippocampus, two brain areas known to have different recovery capacity after MDMA, to test whether BDNF-levels were associated with the long-term recovery of serotonergic fibers after a neurotoxic dose of MDMA. Both TpH IR axon density and [3H]-paroxetine-binding were significantly decreased 3 weeks after the treatment in both brain areas but while normalization in both parameters was found in parietal cortex 24 weeks after treatment, significant decreases remained evident in the hippocampus. In the parietal cortex, a significant reduction in BDNF protein levels was found in the acute phase after treatment (1 day), which was followed by a robust increase 8 weeks later and a return to control levels by 12 weeks. In contrast, no significant alteration of BDNF protein level was found in the hippocampus at any time points. This absence of any significant increase in BDNF protein levels in the hippocampus, and the persistence in this region of decreases in TpH IR axon density and [3H]-paroxetine-binding, raises the possibility that BDNF has an important role in the long-term recovery of serotonergic axons after MDMA treatment.",
keywords = "3,4-Methylenedioxymethamphetamine (ecstasy), Brain derived neurotrophic factor (BDNF), ELISA, Paroxetine-binding, Serotonin, Tryptophan-hydroxylase (TpH)",
author = "C. {\'A}dori and And{\'o}, {R{\'o}me{\'o} D.} and Linda Ferrington and M{\'a}ria Szekeres and Szilvia Vas and Kelly, {Paul A T} and L. Hunyady and G. Bagdy",
year = "2010",
month = "7",
doi = "10.1016/j.neulet.2010.04.061",
language = "English",
volume = "478",
pages = "56--60",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Elevated BDNF protein level in cortex but not in hippocampus of MDMA-treated Dark Agouti rats

T2 - A potential link to the long-term recovery of serotonergic axons

AU - Ádori, C.

AU - Andó, Rómeó D.

AU - Ferrington, Linda

AU - Szekeres, Mária

AU - Vas, Szilvia

AU - Kelly, Paul A T

AU - Hunyady, L.

AU - Bagdy, G.

PY - 2010/7

Y1 - 2010/7

N2 - 3,4-Methylenedioxymethamphetamine (MDMA, " ecstasy" ) is a widely used recreational drug known to cause selective long-term serotonergic damage. In this study, we examined the pattern of BDNF protein expression 1 day, 3, 8, 12 and 24 weeks after a single 15mg/kg i.p. dose of MDMA to adolescent Dark Agouti rats. In parallel, we measured either tryptophan-hydroxylase immunoreactive (TpH IR) axon density, or [3H]-paroxetine-binding in parietal cortex and hippocampus, two brain areas known to have different recovery capacity after MDMA, to test whether BDNF-levels were associated with the long-term recovery of serotonergic fibers after a neurotoxic dose of MDMA. Both TpH IR axon density and [3H]-paroxetine-binding were significantly decreased 3 weeks after the treatment in both brain areas but while normalization in both parameters was found in parietal cortex 24 weeks after treatment, significant decreases remained evident in the hippocampus. In the parietal cortex, a significant reduction in BDNF protein levels was found in the acute phase after treatment (1 day), which was followed by a robust increase 8 weeks later and a return to control levels by 12 weeks. In contrast, no significant alteration of BDNF protein level was found in the hippocampus at any time points. This absence of any significant increase in BDNF protein levels in the hippocampus, and the persistence in this region of decreases in TpH IR axon density and [3H]-paroxetine-binding, raises the possibility that BDNF has an important role in the long-term recovery of serotonergic axons after MDMA treatment.

AB - 3,4-Methylenedioxymethamphetamine (MDMA, " ecstasy" ) is a widely used recreational drug known to cause selective long-term serotonergic damage. In this study, we examined the pattern of BDNF protein expression 1 day, 3, 8, 12 and 24 weeks after a single 15mg/kg i.p. dose of MDMA to adolescent Dark Agouti rats. In parallel, we measured either tryptophan-hydroxylase immunoreactive (TpH IR) axon density, or [3H]-paroxetine-binding in parietal cortex and hippocampus, two brain areas known to have different recovery capacity after MDMA, to test whether BDNF-levels were associated with the long-term recovery of serotonergic fibers after a neurotoxic dose of MDMA. Both TpH IR axon density and [3H]-paroxetine-binding were significantly decreased 3 weeks after the treatment in both brain areas but while normalization in both parameters was found in parietal cortex 24 weeks after treatment, significant decreases remained evident in the hippocampus. In the parietal cortex, a significant reduction in BDNF protein levels was found in the acute phase after treatment (1 day), which was followed by a robust increase 8 weeks later and a return to control levels by 12 weeks. In contrast, no significant alteration of BDNF protein level was found in the hippocampus at any time points. This absence of any significant increase in BDNF protein levels in the hippocampus, and the persistence in this region of decreases in TpH IR axon density and [3H]-paroxetine-binding, raises the possibility that BDNF has an important role in the long-term recovery of serotonergic axons after MDMA treatment.

KW - 3,4-Methylenedioxymethamphetamine (ecstasy)

KW - Brain derived neurotrophic factor (BDNF)

KW - ELISA

KW - Paroxetine-binding

KW - Serotonin

KW - Tryptophan-hydroxylase (TpH)

UR - http://www.scopus.com/inward/record.url?scp=77953609957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953609957&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2010.04.061

DO - 10.1016/j.neulet.2010.04.061

M3 - Article

C2 - 20435092

AN - SCOPUS:77953609957

VL - 478

SP - 56

EP - 60

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -